Venezuela Medical Device Change Control 2026: Variations and Approval Sequencing

1. Key takeaways

Venezuela requires that substantial changes to a device, to its manufacturing process or to its labelling be submitted for approval and cleared before they are implemented. Change types span four families: design, materials, manufacturing process, and labelling and instructions for use.

The conclusion is this: the classification of a change has to be decided during development, not reconstructed after launch. During development there is a complete technical basis on which to argue whether a given change affects an approved conclusion. After launch, that basis is usually no longer assembled, so the argument cannot be made and every change is filed as major by default. The cost difference is not marginal, because a major filing carries a technical dossier, a review cycle and a period during which the change cannot be implemented.

There is a second consequence that is easy to miss. Change classification is a regulatory decision taken inside an engineering or procurement process, often by people who have no reason to know that a supplier substitution can invalidate a sterilization validation. The control point therefore has to sit where the decision is actually made, which means the interface between procurement, operations and regulatory affairs rather than the regulatory department alone.

2. Legal basis

Position statement: the rule that substantial changes require prior approval is a practical estimate widely cited across industry sources, and this verification did not obtain a Venezuelan official instrument that can be cited directly in support of it.

Note how the legal architecture works. The statutory layer says almost nothing about variations: it imposes the registration obligation and leaves the procedure to administrative instruments. The procedure itself now runs through the COMEX platform, and the customs layer is governed separately by Circular DGSACS-008/2026. A change therefore has to be assessed against three questions rather than one: does it alter the approved registration, does it require a platform filing, and does it disturb the labelling authorization that customs relies on.

3. Expert insights

1. The four change families carry different risk weights and should not be treated alike.

The asymmetry in the table is the practical point. Design, material and process changes almost always require the same answer, so the analytical effort is best spent on the fourth row, where the outcome genuinely depends on content. A change to a warning statement and a change to a font size are both labelling changes, but only one of them alters what the label communicates to the user, and only that one should consume review capacity.

2. Subcontractor change is the most frequently overlooked process change. Replacing a sterilization service provider or an assembly subcontractor leaves the product design untouched, yet it invalidates the validation certificates and breaks the traceability chain on which those certificates depend. These decisions are taken in procurement as routine commercial matters while carrying regulatory consequences of the first order, which is why a linkage mechanism between procurement and regulatory affairs is required. The mechanism does not need to be elaborate: a rule that no supplier change in a validated process is executed without a regulatory assessment, and a named person who signs that assessment, is usually enough.

3. The coupling between labelling changes and customs authorization is specific to Venezuela. Circular DGSACS-008/2026 requires that destination labelling be formally authorized. It follows that any change to label content must be accompanied by an update to the label authorization; otherwise a shipment can be stopped at clearance even though the registration change itself was approved. The two approvals are held by different processes and move at different speeds, so the label authorization is the one that has to be sequenced first when a shipment date is fixed.

4. A change ledger is the infrastructure that makes classification possible. The ledger should record the content of the change, the technical basis, the impact analysis (whether safety or effectiveness is affected), the classification conclusion, whether it was notified, and the outcome. Without a ledger every change has to be argued from scratch, at very high cost. With a ledger, a comparable change from two years earlier supplies the precedent, and the marginal cost of the next classification falls sharply.

4. Practical recommendations

1. R&D and regulatory affairs: open the change ledger during development and record the technical basis and impact analysis for each change as the basis for classification.
2. Procurement and regulatory affairs: establish a linkage mechanism so that subcontractor changes and material grade changes are assessed by regulatory affairs before execution.
3. Regulatory affairs leads: process labelling changes and label authorization together to avoid a gap in which the registration change is approved but the clearance authorization has lapsed.
4. Regulatory affairs leads: file borderline cases as major changes, since the risk of downgrading (non-compliance) exceeds the cost of upgrading (time).
5. License holders: complete all change notifications before renewal starts, so that they do not collide with renewal materials (article 41 of this series).

5. Verification checklist

• □ The change ledger is live and maintained from the development stage
• □ A procurement and regulatory linkage mechanism exists (subcontractor and material changes require assessment)
• □ Labelling changes and label authorization are processed in parallel
• □ Borderline cases have been handled as major changes
• □ All changes were notified before renewal was started

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.